scholarly journals Lymph Node Infarction in Classical Hodgkin's Lymphoma

2012 ◽  
Vol 52 (1) ◽  
pp. 35-39 ◽  
Author(s):  
Eiichiro Mori ◽  
Yasunori Enomoto ◽  
Hirokazu Nakamine ◽  
Takahiko Kasai ◽  
Maiko Takeda ◽  
...  
Keyword(s):  
Lymph Node ◽  
Hodgkin’S Lymphoma ◽  
Hodgkin's Lymphoma

scholarly journals Epstein-Barr virus in benign lymph node biopsies from individuals infected with the human immunodeficiency virus is associated with concurrent or subsequent development of non-Hodgkin's lymphoma

Blood ◽  
1991 ◽  
Vol 77 (7) ◽  
pp. 1527-1533 ◽  
Author(s):  
D Shibata ◽  
LM Weiss ◽  
BN Nathwani ◽  
RK Brynes ◽  
AM Levine
Keyword(s):  
Human Immunodeficiency Virus ◽  
Lymph Node ◽  
Hodgkin’S Lymphoma ◽  
Hodgkin's Lymphoma ◽  
Normal Individuals ◽  
Non Hodgkin's Lymphoma ◽  
Immunodeficiency Virus ◽  
Ebv Dna ◽  
Epstein Barr ◽  
Benign Lymph Node

Abstract Individuals infected with the human immunodeficiency virus (HIV) have an increased incidence of high-grade B-cell lymphoma. In many instances, these lymphomas contain Epstein-Barr viral (EBV) genomes. To investigate the role of EBV in development of HIV-related lymphoma, benign fixed lymph node biopsies from normal individuals and HIV- infected individuals with persistent generalized lymphadenopathy (PGL) were analyzed for EBV sequences by polymerase chain reaction and in situ DNA hybridization techniques. EBV DNA was not detected in any of 16 benign lymph node biopsies from normal individuals, but could be detected from 13 of 35 PGL biopsies. The EBV-infected cells were present in both follicular and interfollicular areas and in both small and large lymphoid cells. The presence of detectable amounts of EBV DNA in the 13 PGL biopsies was associated with an increased incidence of concurrent lymphoma at another site (n = 3) or development of lymphoma in time (n = 2). In contrast, only 1 of 22 individuals with EBV- negative PGL biopsies developed lymphoma in time (P less than .05). EBV was detected in all five lymphomas in which tissue was available for subsequent analysis, including the lymphoma that developed in the individual without EBV in his previous PGL biopsy. These findings support the hypothesis that EBV plays a role in development of some HIV- related lymphomas. Detectable EBV lymphoproliferations occur in a few PGL biopsies and are associated with a significant risk of EBV DNA- positive non-Hodgkin's lymphoma.

scholarly journals Translocation (14;18)-positive cells are present in the circulation of the majority of patients with localized (stage I and II) follicular non- Hodgkin's lymphoma

Blood ◽  
1993 ◽  
Vol 82 (8) ◽  
pp. 2510-2516 ◽  
Author(s):  
AC Lambrechts ◽  
PE Hupkes ◽  
LC Dorssers ◽  
MB van't Veer
Keyword(s):  
Bone Marrow ◽  
Lymph Node ◽  
Peripheral Blood ◽  
Hodgkin’S Lymphoma ◽  
Lymph Node Biopsy ◽  
Stage I ◽  
Hodgkin's Lymphoma ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma ◽  
Sensitive Polymerase Chain Reaction

Abstract Stage I and II follicular non-Hodgkin's lymphoma (NHL) is clinically defined as a localized disease. To study the possibility that this disease is in fact disseminated, we used the sensitive polymerase chain reaction (PCR) method using translocation (14;18) as marker. Samples from 21 patients who were clinically diagnosed with stage I or II follicular NHL were analyzed for the presence of t(14;18)-positive cells using PCR. We analyzed (1) the diagnostic lymph node biopsy and (2) the peripheral blood or bone marrow samples from these patients. Translocation (14;18) cells were detected in the diagnostic lymph node biopsies of 12 patients. In 9 of these patients, t(14;18)-positive cells were detected in peripheral blood and/or bone marrow samples at diagnosis and/or after therapy. Thus, in 75% of the follicular NHL patients carrying the t(14;18) as a marker for lymphoma cells, t(14;18)- positive cells were detected in peripheral blood and bone marrow at diagnosis and after therapy. Our results show that t(14;18)-positive cells can be detected in the circulation of patients with stage I and II follicular NHL, indicating that, although diagnosed as localized, the disease is disseminated.

More Than 4 Cycles of ABVD for the Treatment of Stage I–II Hodgkin’s Lymphoma?.

Blood ◽  
2005 ◽  
Vol 106 (11) ◽  
pp. 4719-4719
Author(s):  
Norma Tartas ◽  
Marta Zerga ◽  
Graciela Alfonso ◽  
María P. Amoroso Copello ◽  
Isabel Santos ◽  
...  
Keyword(s):  
Risk Factors ◽  
Lymph Node ◽  
Hodgkin’S Lymphoma ◽  
Residual Disease ◽  
Negative Impact ◽  
Patient Characteristics ◽  
Marrow Transplant ◽  
Stage I ◽  
Hodgkin's Lymphoma ◽  
Bulky Disease

Abstract Patients with stage I-II A non bulky Hodgkin’s lymphoma (HL) are successfully treated with 2–4 cycles of ABVD plus IF radiotherapy (RT). Although the negative impact in DFS and OS of B symptoms and bulky disease(X) is widely accepted, other risk factors such as number of lymph node regions involved or extensive spleen involvement have also been reported. What is the best treatment for such patients? Is radiotherapy necessary? We report here our experience with protocol HD 98 in 62 patients, with stage I–II HL. Since January 98 we have included 30 individuals without risk factors and 32 with one of the following risk factors: B symptoms (n:11), X (n:9), extensive spleen involvement (n:1) and involvement of more than two lymph node regions (n:11). Other patient characteristics were: age: x 31yrs (15–69), sex: females 31, males :31. Ann Arbor stage IA :11, IB :1, IIA: 36, IIB :14. Histologic subtypes were: LP: 4, NS: 42, MC: 15, lymphocyte rich :1. Patients with favourable features received 4 cycles of ABVD plus IFRT, those with unfavourable factors received 6–8 cycles of ABVD plus RT in areas of bulky or residual disease. Results: 59/61 evaluable patients obtained CR or CRu. Two patients were considered primary resistant. Three patients relapsed at 7, 13 and 30 months after completion of treatment. Autologus bone marrow transplant was performed in four patients. The two primary resistant patients relapsed after the transplant and died with proggressive disease. Those patients transplanted in a chemosensitive relapse are currently in CR. With a median follow up of 46m (13–84) 96.7% of the patients are alive, in CR. Conclusions: In our experience patients with unfavourable stages I–II HL are succesfully treated with 6–8 cycles of ABVD. In such patients RT might only be necessary in areas of bulky or residual disease.

Lymphocyte-Predominant Hodgkin’s Lymphoma in Children: Therapeutic Abstention After Initial Lymph Node Resection—A Study of the French Society of Pediatric Oncology

2003 ◽  
Vol 21 (15) ◽  
pp. 2948-2952 ◽  
Author(s):  
B. Pellegrino ◽  
M.J. Terrier-Lacombe ◽  
O. Oberlin ◽  
T. Leblanc ◽  
Y. Perel ◽  
...  
Keyword(s):  
Lymph Node ◽  
Pediatric Oncology ◽  
Hodgkin’S Lymphoma ◽  
Stage I ◽  
Hodgkin's Lymphoma ◽  
French Society ◽  
Complementary Treatment ◽  
Lymph Node Resection ◽  
Initial Surgery

Purpose: To clarify treatment strategy for lymphocyte-predominant Hodgkin’s lymphoma (LPHL), the French Society of Pediatric Oncology initiated a prospective, nonrandomized study in 1988. Patients received either standard treatment for Hodgkin’s lymphoma or were not treated beyond initial adenectomy. Patients and Methods: From 1988 to 1998, 27 patients were available for study. Twenty-four patients were male, and median age was 10 years (range, 4 to 16 years). Twenty-two, two, and three patients had stage I, II, and III disease, respectively. Thirteen patients (stage I, n = 11; stage III, n = 2) received no further treatment after initial surgical adenectomy (SA). Fourteen patients received combined treatment (CT; n = 10), involved-field radiotherapy alone (n = 1), or chemotherapy alone (n = 3). The two groups were comparable for clinical status, treatment, and follow-up. Results: Twenty-three of 27 patients achieved complete remission (CR). With a median follow-up time of 70 months (range, 32 to 214 months), overall survival to date is 100%, and overall event-free survival (EFS) is 69% ± 10% (SA, 42% ± 16%; CT, 90% ± 8.6%; P < .04). If we considered only the patients in CR after initial surgery (n = 12), EFS was no longer significantly different between the two groups. Patients with residual mass after initial surgery (n = 15) had worse EFS if they did not receive complementary treatment (P < .05). Conclusion: Although based on a small number of patients, our study showed that (1) no further therapy is a valid therapeutic approach in LPHL patient in CR after initial lymph node resection, and (2) complementary treatment diminishes relapse frequency but has no impact on survival.

scholarly journals Epstein-Barr virus in benign lymph node biopsies from individuals infected with the human immunodeficiency virus is associated with concurrent or subsequent development of non-Hodgkin's lymphoma

Blood ◽  
1991 ◽  
Vol 77 (7) ◽  
pp. 1527-1533 ◽  
Author(s):  
D Shibata ◽  
LM Weiss ◽  
BN Nathwani ◽  
RK Brynes ◽  
AM Levine
Keyword(s):  
Human Immunodeficiency Virus ◽  
Lymph Node ◽  
Hodgkin’S Lymphoma ◽  
Hodgkin's Lymphoma ◽  
Normal Individuals ◽  
Non Hodgkin's Lymphoma ◽  
Immunodeficiency Virus ◽  
Ebv Dna ◽  
Epstein Barr ◽  
Benign Lymph Node

Individuals infected with the human immunodeficiency virus (HIV) have an increased incidence of high-grade B-cell lymphoma. In many instances, these lymphomas contain Epstein-Barr viral (EBV) genomes. To investigate the role of EBV in development of HIV-related lymphoma, benign fixed lymph node biopsies from normal individuals and HIV- infected individuals with persistent generalized lymphadenopathy (PGL) were analyzed for EBV sequences by polymerase chain reaction and in situ DNA hybridization techniques. EBV DNA was not detected in any of 16 benign lymph node biopsies from normal individuals, but could be detected from 13 of 35 PGL biopsies. The EBV-infected cells were present in both follicular and interfollicular areas and in both small and large lymphoid cells. The presence of detectable amounts of EBV DNA in the 13 PGL biopsies was associated with an increased incidence of concurrent lymphoma at another site (n = 3) or development of lymphoma in time (n = 2). In contrast, only 1 of 22 individuals with EBV- negative PGL biopsies developed lymphoma in time (P less than .05). EBV was detected in all five lymphomas in which tissue was available for subsequent analysis, including the lymphoma that developed in the individual without EBV in his previous PGL biopsy. These findings support the hypothesis that EBV plays a role in development of some HIV- related lymphomas. Detectable EBV lymphoproliferations occur in a few PGL biopsies and are associated with a significant risk of EBV DNA- positive non-Hodgkin's lymphoma.

scholarly journals The Dangers of Immediately Performing a Sensitive and Specific Investigation versus the Dangers of Delaying It: A Cautionary Case of Hodgkin’s Lymphoma

2020 ◽  
Author(s):  
Takahiro Ito ◽  
Hiroshi Sawachika ◽  
Yukinori Harada ◽  
Taro Shimizu
Keyword(s):  
Lymph Node ◽  
Hodgkin’S Lymphoma ◽  
Gastrointestinal Endoscopy ◽  
Lymph Node Biopsy ◽  
Hodgkin's Lymphoma ◽  
Haemophagocytic Lymphohistiocytosis ◽  
Gastrointestinal Malignancies ◽  
Node Biopsy ◽  
History Of ◽  
Diagnostic Outcome

A 60-year-old man was admitted with a 1-month history of fever and weight loss. Multiple lymphadenopathies and haemophagocytic lymphohistiocytosis were noted from the beginning, suggesting lymphoma. However, lymph node biopsy was deferred because lymph node biopsy was regarded as being invasive and requires general anaesthesia, and because other possible differential diagnoses including gastrointestinal malignancies and TAFRO syndrome were being considered. Instead, investigations including gastrointestinal endoscopy and bone marrow biopsy were prioritized. The patient was eventually diagnosed with Hodgkin’s lymphoma based on lymph node biopsy but died during chemotherapy. Physicians should prioritize the tests that are most directly related to the diagnostic outcome, even if they are invasive.

Primary laryngeal lymphoma in China: a retrospective study of the last 25 years

2019 ◽  
Vol 133 (09) ◽  
pp. 792-795
Author(s):  
P Zhao ◽  
Y Zhou ◽  
J Li
Keyword(s):  
Lymph Node ◽  
T Cell ◽  
Hodgkin’S Lymphoma ◽  
Chinese Language ◽  
Lymph Node Involvement ◽  
Hodgkin's Lymphoma ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma ◽  
Node Involvement ◽  
Language Literature

AbstractObjectiveTo retrospectively study the primary laryngeal lymphoma cases in China reported in Chinese-language literature.MethodChinese-language literature was searched for papers on primary laryngeal lymphoma published in the last 25 years.ResultsThe selected papers comprised a total of 115 cases. The male-to-female ratio was 3.4:1. Non-Hodgkin's lymphoma was the exclusive pathological type. The estimated 3-year, 5-year and 10-year survival rates were 70.9 ± 6.4 per cent, 63.4 ± 7.6 per cent and 56.4 ± 9.5 per cent respectively, as determined by Kaplan–Meier analysis. B-cell non-Hodgkin's lymphoma patients had a better prognosis than T-cell non-Hodgkin's lymphoma patients (p = 0.032). Patients with lymph node involvement at diagnosis had a poorer prognosis (p &lt; 0.01).ConclusionPrimary laryngeal lymphoma is a rare disease with no specific clinical features. More than one biopsy might be needed to obtain the correct diagnosis. Proper treatment could lead to promising outcomes. The T-cell subtype and lymph node involvement at diagnosis might indicate worse prognosis.

scholarly journals Coexistence of Hodgkin’s Lymphoma and Castleman’s Disease: A Case Report with Successful Response to Chemotherapy and Radiotherapy

2013 ◽  
Vol 2013 ◽  
pp. 1-4 ◽  
Author(s):  
Amina Mohtaram ◽  
Mohammed Afif ◽  
Tanae Sghiri ◽  
Amal Rami ◽  
Rachida Latib ◽  
...  
Keyword(s):  
Lymph Node ◽  
Hodgkin's Disease ◽  
Cervical Lymph Node ◽  
Hodgkin’S Lymphoma ◽  
Hodgkin’S Disease ◽  
Castleman’S Disease ◽  
Hodgkin's Lymphoma ◽  
Castleman's Disease ◽  
Cervical Lymph Nodes ◽  
Response To Chemotherapy

Background. Castleman’s disease is a rare clinicopathological entity of unknown origin. Coexistence of Hodgkin’s lymphoma and Castleman’s disease is rare. We report a case of Hodgkin’s disease of cervical lymph nodes in a patient previously diagnosed with Castleman’s disease.Case Presentation. A 43-year-old man admitted in July 2009 for a right cervical pain with lymph node at the physician examination. He underwent a right adenectomy and histological studies showed typical features of Castleman’s disease. Three years after, the patient consulted for increasing the volume of cervical lymph node. Clinical examination showed a right cervical lymph node of 3 cm. The computed tomography scan of chest, abdominal and pelvic was normal. Histological and immunohistochemical studies of cervical lymph node biopsy specimen were in favor of Castleman’s disease associated with Hodgkin’s disease. Reed-Sternberg cells were positive for CD15 and CD30. The patient received chemotherapy based on anthracyclines, bleomycin, vinblastine, and dacarbazine (ABVD) and radiotherapy with complete response.Conclusion. Prevalence of Hodgkin’s lymphoma in Castleman’s disease is more difficult to establish because of the low number of cases reported in the literature.

Sign in / Sign up

Export Citation Format

Share Document